Table 2.
Unadjusted Hazard Ratios for Association of Placebo Adherence with Mortality and Incident Events in the SOLVD Treatment Trial
| Lower adherent participants (N = 98) | Higher adherenta participants (N = 1,157) | |||
|---|---|---|---|---|
| Outcome | No. events | No. events | HR | 95% CI |
| Total mortality | 45 | 446 | 0.52 | 0.38–0.71 |
| CVD mortality | 41 | 402 | 0.52 | 0.38–0.72 |
| Non-CVD mortality | 4 | 44 | 0.53 | 0.19–1.48 |
| CHD mortality | 3 | 59 | 0.96 | 0.30–3.08 |
| Incident CVD events (fatal and non-fatal) | 85 | 855 | 0.46 | 0.36–0.57 |
| Incident CHD events (fatal and non-fatal) | 11 | 130 | 0.54 | 0.29–1.00 |
Legend:
CHD = Coronary heart disease
CVD = Cardiovascular disease
CI = Confidence interval
a“Higher adherent” defined as ≥75% total in-study placebo medication adherence
Significant differences (p < 0.05) indicated in bold type